Abramsky O, Litvin Y
Perspect Biol Med. 1978 Autumn;22(1):104-14.
Clinical and neuropharmacological evidence indicates the involvement of dopaminergic mechanisms in Parkinson's disease and schizophrenia, as well as in iatrogenic Parkinsonism and drug-induced schizophrenia-like syndrome. The evidence hitherto presented stresses the existence of a reversed relationship between Parkinson's disease and schizophrenia and implicates the possibility that dysfunction of dopamine-receptors may be a central phenomenon in both diseases. In view of the recent demonstration of two separate dopamine-receptors, it is postulated that a striatal receptor blockade may cause Parkinson's disease, whereas a limbic receptor blockade may result in schizophrenia. The recent discovery that several autoimmune diseases, such as myasthenia gravis, are the result of an immunopharmacological block at receptor sites, together with several observations of immunological disorders in Parkinson's disease and schizophrenia, suggests the possibility that certain types of Parkinson's disease and schizophrenia might be the consequence of an autoimmune blockade of striatal or limbic dopamine-receptors, respectively.
临床和神经药理学证据表明,多巴胺能机制与帕金森病和精神分裂症有关,也与医源性帕金森综合征和药物诱发的精神分裂症样综合征有关。迄今所呈现的证据强调了帕金森病和精神分裂症之间存在反向关系,并暗示多巴胺受体功能障碍可能是这两种疾病的核心现象。鉴于最近发现了两种不同的多巴胺受体,有人推测纹状体受体阻断可能导致帕金森病,而边缘系统受体阻断可能导致精神分裂症。最近发现几种自身免疫性疾病,如重症肌无力,是受体部位免疫药理学阻断的结果,同时对帕金森病和精神分裂症中免疫紊乱的若干观察结果表明,某些类型的帕金森病和精神分裂症可能分别是纹状体或边缘系统多巴胺受体自身免疫性阻断的结果。